Zentalis Pharmaceuticals granted 191,000 non-qualified stock options to two newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $3.98, matching the stock's closing price on the grant date, a 10-year term, and vest over four years. This move supports Zentalis' growth as it advances its investigational cancer treatment azenosertib. The inducement plan is designed to attract new talent to the company, aiding its development and commercialization efforts.
Virginia Governor Abigail Spanberger signed House Bill 655 and Senate Bill 346, reforming zoning laws to allow manufactured homes in areas where site-built homes are permitted. The laws prevent local governments from imposing stricter rules on manufa...
Royalton Hotels & Resorts has officially opened the Royalton Vessence Barbados, a new all-inclusive resort designed exclusively for adults on Barbados' Platinum Coast. This resort introduces a transformative concept focused on immersive, personalized...
Bitcoin is facing increased selling pressure after breaking below crucial support levels, including the 50-day, 100-day, and 200-day moving averages. The cryptocurrency has slipped into the $71,000-$72,000 range, losing the ascending trendline that h...
XRP is facing a crucial support level around $1.30 after months in a descending triangle pattern, signaling strong bearish control. The cryptocurrency has formed lower highs since March, with resistance from moving averages and a weak long-term trend...
LAB token jumped 65.16% to $16.49, leading altcoin gains driven by a new strategic partnership with a major biotech firm. This partnership has sparked investor interest in LAB's decentralized laboratory services. Other notable altcoin movers include ...
